GT200900284A - Dosis intravenosa y oral de un inhibidor p2y12 de accion directa y reversible.- - Google Patents
Dosis intravenosa y oral de un inhibidor p2y12 de accion directa y reversible.-Info
- Publication number
- GT200900284A GT200900284A GT200900284A GT200900284A GT200900284A GT 200900284 A GT200900284 A GT 200900284A GT 200900284 A GT200900284 A GT 200900284A GT 200900284 A GT200900284 A GT 200900284A GT 200900284 A GT200900284 A GT 200900284A
- Authority
- GT
- Guatemala
- Prior art keywords
- reversible
- direct
- intravenous
- inhibitor
- oral dose
- Prior art date
Links
- 230000002441 reversible effect Effects 0.000 title abstract 2
- 239000002172 P2Y12 inhibitor Substances 0.000 title 1
- 238000001990 intravenous administration Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91564907P | 2007-05-02 | 2007-05-02 | |
| US94792107P | 2007-07-03 | 2007-07-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GT200900284A true GT200900284A (es) | 2012-01-31 |
Family
ID=39587015
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GT200900284A GT200900284A (es) | 2007-05-02 | 2009-10-30 | Dosis intravenosa y oral de un inhibidor p2y12 de accion directa y reversible.- |
Country Status (17)
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA017402B1 (ru) * | 2005-11-03 | 2012-12-28 | Портола Фармасьютикалз, Инк. | [4-(6-галоген-7-замещенные-2,4-диоксо-1,4-дигидро-2н-хиназолин-3-ил)фенил]-5-хлортиофен-2-илсульфонилмочевины, их формы, способы получения соединений, фармацевтические композиции, содержащие эти соединения, и их применение |
| BRPI0808422A2 (pt) * | 2007-03-06 | 2015-06-23 | Novartis Ag | Compostos orgânicos bicíclicos adequados para o tratamento de condições inflamatórias ou alérgicas |
| CN101720324A (zh) * | 2007-05-02 | 2010-06-02 | 波托拉医药品公司 | [4-(6-氟-7-甲基氨基-2,4-二氧代-1,4-二氢-2h-喹唑啉-3-基)-苯基]-5-氯-噻吩-2-基-磺酰基脲盐、其相关的形式和方法 |
| US20090156620A1 (en) * | 2007-05-02 | 2009-06-18 | Portola Pharmaceuticals, Inc. | [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto |
| US9427448B2 (en) * | 2009-11-11 | 2016-08-30 | The Medicines Company | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
| CN106075455A (zh) * | 2008-12-30 | 2016-11-09 | 丹麦国家医院 | 鉴定发展成器官功能衰竭的风险提高的危重患者的方法及用于其治疗的化合物 |
| US10376532B2 (en) | 2009-11-11 | 2019-08-13 | Chiesi Farmaceutici, S.P.A. | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
| DK2498731T3 (da) | 2009-11-11 | 2020-03-02 | Chiesi Farm Spa | Fremgangsmåder til behandling eller forebyggelse af stenttrombose |
| CA2785487C (en) * | 2009-12-23 | 2017-11-28 | Ratiopharm Gmbh | Solid pharmaceutical dosage form of ticagrelor |
| US20130165459A1 (en) | 2010-01-12 | 2013-06-27 | Norvartis Pharma Ag | Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof |
| WO2011137459A1 (en) * | 2010-04-30 | 2011-11-03 | Portola Pharmaceuticals, Inc. | Dosage forms of elinogrel and methods of injectable administration thereof |
| WO2012072743A1 (en) * | 2010-12-01 | 2012-06-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method and kits for determining platelet susceptibility to activation in a patient |
| US8987285B2 (en) * | 2010-12-03 | 2015-03-24 | Portola Pharmaceuticals, Inc. | Pharmaceutical compositions, dosage forms and new forms of the compound of formula (I), and methods of use thereof |
| MX393334B (es) | 2017-03-15 | 2025-03-24 | Idorsia Pharmaceuticals Ltd | Administración subcutánea de un antagonista del receptor p2y12. |
| MA49452A (fr) | 2017-06-23 | 2021-05-05 | Chiesi Farm Spa | Procédé de prévention de thrombose de shunt de l'artère systémique-pulmonaire |
| CN107462648B (zh) * | 2017-08-21 | 2019-09-27 | 盐城锦明药业有限公司 | 一种Cangrelor中间体腺苷-2-硫酮的高效液相色谱检测方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6906063B2 (en) | 2000-02-04 | 2005-06-14 | Portola Pharmaceuticals, Inc. | Platelet ADP receptor inhibitors |
| EA017402B1 (ru) | 2005-11-03 | 2012-12-28 | Портола Фармасьютикалз, Инк. | [4-(6-галоген-7-замещенные-2,4-диоксо-1,4-дигидро-2н-хиназолин-3-ил)фенил]-5-хлортиофен-2-илсульфонилмочевины, их формы, способы получения соединений, фармацевтические композиции, содержащие эти соединения, и их применение |
-
2008
- 2008-05-02 WO PCT/US2008/062518 patent/WO2008137753A2/en not_active Ceased
- 2008-05-02 EA EA200901473A patent/EA200901473A1/ru unknown
- 2008-05-02 MX MX2009011843A patent/MX2009011843A/es not_active Application Discontinuation
- 2008-05-02 KR KR1020097025059A patent/KR20100029746A/ko not_active Withdrawn
- 2008-05-02 CA CA002686203A patent/CA2686203A1/en not_active Abandoned
- 2008-05-02 EP EP08747561A patent/EP2079464A2/en not_active Withdrawn
- 2008-05-02 AU AU2008247483A patent/AU2008247483A1/en not_active Abandoned
- 2008-05-02 BR BRPI0811476-5A2A patent/BRPI0811476A2/pt not_active IP Right Cessation
- 2008-05-02 US US12/114,630 patent/US20090048216A1/en not_active Abandoned
- 2008-05-02 CN CN200880023071A patent/CN101795682A/zh active Pending
- 2008-05-02 JP JP2010506688A patent/JP2010526101A/ja not_active Withdrawn
-
2009
- 2009-10-29 IL IL201834A patent/IL201834A0/en unknown
- 2009-10-30 TN TNP2009000451A patent/TN2009000451A1/fr unknown
- 2009-10-30 GT GT200900284A patent/GT200900284A/es unknown
- 2009-11-26 MA MA32377A patent/MA31663B1/fr unknown
- 2009-12-02 EC EC2009009778A patent/ECSP099778A/es unknown
- 2009-12-02 CO CO09137697A patent/CO6241104A2/es not_active Application Discontinuation
-
2011
- 2011-09-16 US US13/235,305 patent/US20120009172A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2079464A2 (en) | 2009-07-22 |
| IL201834A0 (en) | 2010-06-16 |
| KR20100029746A (ko) | 2010-03-17 |
| CA2686203A1 (en) | 2008-11-13 |
| ECSP099778A (es) | 2010-01-29 |
| EA200901473A1 (ru) | 2010-06-30 |
| CO6241104A2 (es) | 2011-01-20 |
| BRPI0811476A2 (pt) | 2014-11-04 |
| US20090048216A1 (en) | 2009-02-19 |
| CN101795682A (zh) | 2010-08-04 |
| TN2009000451A1 (en) | 2011-03-31 |
| JP2010526101A (ja) | 2010-07-29 |
| WO2008137753A2 (en) | 2008-11-13 |
| AU2008247483A1 (en) | 2008-11-13 |
| MX2009011843A (es) | 2010-04-22 |
| WO2008137753A3 (en) | 2009-02-12 |
| MA31663B1 (fr) | 2010-09-01 |
| US20120009172A1 (en) | 2012-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GT200900284A (es) | Dosis intravenosa y oral de un inhibidor p2y12 de accion directa y reversible.- | |
| AR068185A1 (es) | Composiciones de tabletas de desintegracion oral de lamotrigina | |
| CL2019000821A1 (es) | Composiciones, métodos y usos para inhibir la actividad arginasa. (divisional solicitud 201801134) | |
| CL2013001136A1 (es) | Un agente inhibitorio de la fosfodiesterasa 7 (pde7) para ser usado en el tratamiento o la reduccion de la posibilidad de una adiccion; y composicion farmaceutica, forma de dosificacion unitaria y kit farmaceutico que incluyen al inhibidor de fosfodiesterasa 7 (pde7) y un agente terapeutico adicional. | |
| SV2009003335A (es) | Formulaciones para el cancer | |
| PA8850801A1 (es) | Compuestos útiles para inhibir chk1 | |
| MX2020011397A (es) | Compuestos inhibidores de isocitrato deshidrogenasa 2 (idh2) y el uso de los mismos. | |
| HN2011000629A (es) | Derivados de picolinamida como inhibidores de cinasa | |
| AR045179A1 (es) | Uso de una combinacion de un inhibidor de la quinasa del receptor del factor de crecimiento epidermico y de agentes citotoxicos para el tratamiento e inhibicion del cancer | |
| CL2010001361A1 (es) | Compuestos derivados de piperidin-carboxamida, inhibidores de renina; composicion farmaceutica que los comprende; y uso en el tratamiento o prevencion de una enfermedad circulatoria, hipertension y/o diversos daños organicos atribuibles a la hipertension. | |
| BR112015020466A8 (pt) | inibidores de cdc7, seus usos, e composição farmacêutica | |
| GT200900008A (es) | Derivados novedosos de aminopiridina que tienen acción inhibidora selectiva sobre aurora a | |
| DOP2012000290A (es) | 4-yodo-3-nitrobenzamida en combinacion con agentes anti-tumorales para el uso en el tratamiento de cancer utero y cancer de ovario | |
| ECSP088218A (es) | Bencimidazoles sustituidos como inhibidores de cinasa | |
| CL2009000625A1 (es) | Composicion farmaceutica que comprende a)un primer poliol seleccionado de manitol, sorbitol o una combinacion de ambos, b)segundo poliol seleccionado de propilenglicol, glicerina o una combinacion de ambas, c)complejo de borato en un 0,5% p/v de la composicion total, d)preservante, e)agua; util para el tratamiento del ojo. | |
| CL2012000333A1 (es) | Antagonista del receptor de la endotelina útil en la prevención o el tratamiento de metástasis cerebral en combinación con un agente de quimioterapia citotóxico, radioterapia o ambos; su uso para inhibir protección mediada por astrocito de una célula cerebral metastasica de una muerte celular inducida por quimioterapia citotóxica; y su uso para tratar un tumor cerebral metastásico. | |
| CR11418A (es) | Trans-clomifeno para el sindrome metabolico | |
| AR083395A1 (es) | Derivado peptidico nmu (neuromedina u) con elevado efecto anorectico | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| CL2008000610A1 (es) | Composicion en forma de dosificacion transdermica o transmucosa que comprende una relacion en peso de buprenorfina a naloxona entre 2,1:1 y 8:1, util para el tratamiento del dolor. | |
| MX2015010139A (es) | Composicion antiseptica oral para tratamiento de mucositis oral. | |
| CL2011000806A1 (es) | Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular. | |
| CL2009001841A1 (es) | Uso de una composición de liberación sostenida de 4-aminopiridina para preparar un medicamento útil para tratar esclerosis multiple en un sujeto. | |
| PA8784901A1 (es) | Utilizacion de un antagonista par1 en el tratamiento de la fibrilacion atrial | |
| IT1398773B1 (it) | Sequenze oligonucleotidiche inibitrici dell'espressione della chimera ciclina d1/trop2 e loro uso in campo medico. |